CoChat

The Hidden Story of Heterogeneous B-raf V600E Mutation Quantitative Protein Expression in Metastatic Melanoma—Association with Clinical Outcome and Tumor Phenotypes

Open access
Betancourt, Lazaro Hiram, Szasz, A. Marcell, Kuras, Magdalena, Rodriguez Murillo, Jimmy, Sugihara, Yutaka, Pla, Indira, Horvath, Zsolt, Pawłowski, Krzysztof, Rezeli, Melinda, Miharada, Kenichi, Gil, Jeovanis, Eriksson, Jonatan, Appelqvist, Roger, Miliotis, Tasso, Baldetorp, Bo, Ingvar, Christian, Olsson, Håkan, Lundgren, Lotta, Horvatovich, Peter, Welinder, Charlotte, Wieslander, Elisabet, Kwon, Ho Jeong, Malm, Johan, Nemeth, Istvan Balazs, Jönsson, Göran, Fenyö, David, Sanchez, Aniel, Marko-Varga, György · 2019 · Cancers

Published version of a preprint

The DOI matches its Crossref record; 63 of the 64 references it cites were found in a registry or an index.

Abstract

In comparison to other human cancer types, malignant melanoma exhibits the greatest amount of heterogeneity. After DNA-based detection of the BRAF V600E mutation in melanoma patients, targeted inhibitor treatment is the current recommendation. This approach, however, does not take the abundance of the therapeutic target, i.e., the B-raf V600E protein, into consideration. As shown by immunohistochemistry, the protein expression profiles of metastatic melanomas clearly reveal the existence of inter- and intra-tumor variability. Nevertheless, the technique is only semi-quantitative. To quantitate the mutant protein there is a fundamental need for more precise techniques that are aimed at defining the currently non-existent link between the levels of the target protein and subsequent drug efficacy. Using cutting-edge mass spectrometry combined with DNA and mRNA sequencing, the mutated B-raf protein within metastatic tumors was quantitated for the first time. B-raf V600E protein analysis revealed a subjacent layer of heterogeneity for mutation-positive metastatic melanomas. These were characterized into two distinct groups with different tumor morphologies, protein profiles and patient clinical outcomes. This study provides evidence that a higher level of expression in the mutated protein is associated with a more aggressive tumor progression. Our study design, comprised of surgical isolation of tumors, histopathological characterization, tissue biobanking, and protein analysis, may enable the eventual delineation of patient responders/non-responders and subsequent therapy for malignant melanoma.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/cancers11121981

Cites

63 of 63 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Immunohistochemical images of mutated B-raf V600E, displayed from two patients with malignant melanoma. (A) a patient with homogeneous B-raf expression, (B) two IHC images generated from two different areas of the same tumor with heterogeneous and dispersed B-raf expression, highlighted by brown colorimetric reaction. Note the grouping cells (dashed lines) with a more pronounced B-raf V600E expression pattern by brown discoloration of the HRP-DAB reaction.
Figure 1 Immunohistochemical images of mutated B-raf V600E, displayed from two patients with malignant melanoma. (A) a patient with homogeneous B-raf expression, (B) two IHC images generated from two different areas of the same tumor with heterogeneous and dispersed B-raf expression, highlighted by brown colorimetric reaction. Note the grouping cells (dashed lines) with a more pronounced B-raf V600E expression pattern by brown discoloration of the HRP-DAB reaction.CC BY · PubMed Central
Figure 2 General schematic of the workflow followed for identification and quantitation of B-raf V600E from metastatic melanoma patients. Sample processing consisted of automatic generation of protein extracts from patient tumor samples, protein denaturation and tryptic digestion on a robotic micro-chromatographic platform, TMT 11-plex labelling of generated peptides, and peptide fractionation by high pH RP-HPLC. Fractions were analyzed by LC-MS/MS and the processed data searched against the human protein database (see Materials and Methods). Identification and quantitation of the B-raf V600E mutation and the proteins expressed by individual melanoma tumors (global proteomic analysis) including WT B-raf was then performed.
Figure 2 General schematic of the workflow followed for identification and quantitation of B-raf V600E from metastatic melanoma patients. Sample processing consisted of automatic generation of protein extracts from patient tumor samples, protein denaturation and tryptic digestion on a robotic micro-chromatographic platform, TMT 11-plex labelling of generated peptides, and peptide fractionation by high pH RP-HPLC. Fractions were analyzed by LC-MS/MS and the processed data searched against the human protein database (see Materials and Methods). Identification and quantitation of the B-raf V600E mutation and the proteins expressed by individual melanoma tumors (global proteomic analysis) including WT B-raf was then performed.CC BY · PubMed Central
Figure 3 Identification of peptides from B-raf V600E and B-raf WT by mass spectrometry. (A) Assigned MS/MS spectrum of the TMT-labeled peptide IGDFGLATEK from B-raf V600E. Interpretation of the data showed the substitution of valine residue for glutamic acid (Glu, m/ztheo = 129.0425) that corresponds to the mutation. (B) Assigned MS/MS spectrum of the TMT-labeled peptide IGDFGLATVK from WT B-raf. Interpretation of the data showed the presence of the expected valine residue (Val, m/ztheo = 99.0684). The low m/z region is highlighted in both MS/MS spectra to indicate the presence of TMT 11-plex reporter ions that are used to relatively quantify the protein to provide a measure of protein expression.
Figure 3 Identification of peptides from B-raf V600E and B-raf WT by mass spectrometry. (A) Assigned MS/MS spectrum of the TMT-labeled peptide IGDFGLATEK from B-raf V600E. Interpretation of the data showed the substitution of valine residue for glutamic acid (Glu, m/ztheo = 129.0425) that corresponds to the mutation. (B) Assigned MS/MS spectrum of the TMT-labeled peptide IGDFGLATVK from WT B-raf. Interpretation of the data showed the presence of the expected valine residue (Val, m/ztheo = 99.0684). The low m/z region is highlighted in both MS/MS spectra to indicate the presence of TMT 11-plex reporter ions that are used to relatively quantify the protein to provide a measure of protein expression.CC BY · PubMed Central
Figure 4 Patient clinical data and BRAF status for metastatic melanoma. (A) Heat map representation of patient clinical data and BRAF determination by genomic and proteomic techniques. (B) Plot of relative abundance of B-raf V600E protein against a reference sample.
Figure 4 Patient clinical data and BRAF status for metastatic melanoma. (A) Heat map representation of patient clinical data and BRAF determination by genomic and proteomic techniques. (B) Plot of relative abundance of B-raf V600E protein against a reference sample.CC BY · PubMed Central
Figure 5 B-raf V600E expression correlated with patient survival and tumor phenotype. (A) Overall survival (OS) of malignant melanoma patients according to B-raf V600E mutation levels (log-rank p = 0.001, Breslow p = 0.002 and Tarone Ware p = 0.001). (B) Histological images of mutation-positive metastatic melanoma samples: (a and b) tumors MM114 and MM111 with high expression of the B-raf V600E mutated protein; and tumor (c and d) tumors MM147 and MM120 with low expression of the B-raf V600E mutated protein. For all images the magnification and scale were 10× and 50 µm, respectively. (C) Hierarchical clustering heat map of 697 differentially expressed proteins between the two groups of mutation-positive metastatic melanomas. (D) PCA of the two groups of mutation-positive metastatic melanomas based on the differentially expressed proteins. Tumor samples from each group are highlighted in common colors: high B-raf V600E expression (V600E_H, green), low B-raf V600E expression (V600E_L, yellow).
Figure 5 B-raf V600E expression correlated with patient survival and tumor phenotype. (A) Overall survival (OS) of malignant melanoma patients according to B-raf V600E mutation levels (log-rank p = 0.001, Breslow p = 0.002 and Tarone Ware p = 0.001). (B) Histological images of mutation-positive metastatic melanoma samples: (a and b) tumors MM114 and MM111 with high expression of the B-raf V600E mutated protein; and tumor (c and d) tumors MM147 and MM120 with low expression of the B-raf V600E mutated protein. For all images the magnification and scale were 10× and 50 µm, respectively. (C) Hierarchical clustering heat map of 697 differentially expressed proteins between the two groups of mutation-positive metastatic melanomas. (D) PCA of the two groups of mutation-positive metastatic melanomas based on the differentially expressed proteins. Tumor samples from each group are highlighted in common colors: high B-raf V600E expression (V600E_H, green), low B-raf V600E expression (V600E_L, yellow).CC BY · PubMed Central
Figure 6 (A) Canonical pathways overrepresented by proteins differentially expressed in samples with low and high expressions of B-raf V600E. Blue: on average, pathway members have a lower expression of B-raf V600E_high samples. Red/orange: on average, pathway members have a higher expression of B-raf V600E_high samples. (B) One of the top IPA relational protein subnetworks (blue) significantly downregulated in samples with a high expression of B-raf V600E. The tumor suppressor PML is highlighted. (C) One of the top IPA relational protein subnetworks (red) significantly upregulated in samples with a high expression of B-raf V600E. The oncogene MYC is highlighted.
Figure 6 (A) Canonical pathways overrepresented by proteins differentially expressed in samples with low and high expressions of B-raf V600E. Blue: on average, pathway members have a lower expression of B-raf V600E_high samples. Red/orange: on average, pathway members have a higher expression of B-raf V600E_high samples. (B) One of the top IPA relational protein subnetworks (blue) significantly downregulated in samples with a high expression of B-raf V600E. The tumor suppressor PML is highlighted. (C) One of the top IPA relational protein subnetworks (red) significantly upregulated in samples with a high expression of B-raf V600E. The oncogene MYC is highlighted.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 63 references

Research works printed but not linked: 1

  1. Balch, 2001, Prognostic Factors Analysis of 17, 600 Melanoma Patients: Melanoma Staging System, Society, 19, 3622

Cited by

See all 24

Metadata

Authors
Betancourt, L. H., Szasz, A. M., Kuras, M., Rodriguez Murillo, J., Sugihara, Y., Pla, I., Horvath, Z., Pawłowski, K., Rezeli, M., Miharada, K., Gil, J., Eriksson, J., Appelqvist, R., Miliotis, T., Baldetorp, B., Ingvar, C., Olsson, H., Lundgren, L., Horvatovich, P., Welinder, C., Wieslander, E., Kwon, H. J., Malm, J., Nemeth, I. B., Jönsson, G., Fenyö, D., Sanchez, A., & Marko-Varga, G.
Affiliations
  • Lund University (SE)
  • Clinical Protein Science & Imaging, Biomedical Centre, Department of Biomedical, Engineering, Lund University, BMC D13, 221 84 Lund, Sweden
  • Division of Physiological Chemistry I, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, SE-17 177 Stockholm, Sweden
  • Section for Clinical Chemistry, Department of Translational Medicine, Lund University, Skåne University Hospital Malmö, 205 02 Malmö, Sweden
  • Warsaw University of Life Sciences (PL)
  • AstraZeneca (Sweden) (SE)
  • Division of Oncology and Pathology, Department of Clinical Sciences Lund, Lund University, 221 85 Lund, Sweden
  • University of Groningen (NL)
  • Yonsei University (KR)
  • Department of Dermatology and Allergology, University of Szeged, H-6720 Szeged, Hungary
  • NYU Langone Health (US)
Venue
Cancers
Publisher
MDPI AG
Published
2019-12-09
Volume
11
Issue
12
Pages
1981
ISSN
2072-6694 (ISSN-L)
OpenAlex
W2982318968
Cited by
24
References
64
Citations by year
2025: 2 · 2023: 3 · 2022: 2 · 2021: 7 · 2020: 6 · 2019: 3
FWCI
1.49
Type
journal article
Language
en
Open access
Locations
  • Cancers (publishedVersion, cc-by)
  • Preprints.org (acceptedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • University of Groningen research database (University of Groningen / Centre for Information Technology) (publishedVersion, cc-by)
  • Lund University Publications (Lund University) (submittedVersion)
  • University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, cc-by)
Funders
  • Nemzeti Kutatási, Fejlesztési és Innovaciós Alap (KNN121510)
  • Berta Kamprad Foundation (01)
  • ThermoFisher Scientific (01)
  • Liconic Biobanking (01)
  • Global (01)
  • National Research Foundation of Korea (2015K1A1A2028365 and 2016K2A9A1A03904900)
  • Korean Government (2016K2A9A1A03904900)
  • Brain Korea 21 (01)
  • Republic of Korea (01)
  • NIH/NCI International Cancer Proteogenome Consortium (01)
  • The Mats Paulsson Trust (01)
  • The Stefan Paulsson Trust (01)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
  • Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Keywords
metastatic melanoma, BRAF V600E mutation, protein quantification, intratumoral heterogeneity, intertumoral heterogeneity, tumor phenotype, clinical outcomes, targeted therapy, drug response prediction, tumor progression

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The Hidden Story of Heterogeneous B-raf V600E Mutation Quantitative Protein Expression in Metastatic Melanoma—Association with Clinical Outcome and Tumor Phenotypes. https://app.cochat.ai/papers/10.3390/cancers11121981
The paper
Betancourt, L. H., Szasz, A. M., Kuras, M., Rodriguez Murillo, J., Sugihara, Y., Pla, I., Horvath, Z., Pawłowski, K., Rezeli, M., Miharada, K., Gil, J., Eriksson, J., Appelqvist, R., Miliotis, T., Baldetorp, B., Ingvar, C., Olsson, H., Lundgren, L., Horvatovich, P., . . . Marko-Varga, G. (2019). The Hidden Story of Heterogeneous B-raf V600E Mutation Quantitative Protein Expression in Metastatic Melanoma—Association with Clinical Outcome and Tumor Phenotypes. Cancers. https://doi.org/10.3390/cancers11121981

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.